WO1995034320A3 - Methods for inhibiting antigen specific t cell responses - Google Patents

Methods for inhibiting antigen specific t cell responses Download PDF

Info

Publication number
WO1995034320A3
WO1995034320A3 PCT/US1995/007351 US9507351W WO9534320A3 WO 1995034320 A3 WO1995034320 A3 WO 1995034320A3 US 9507351 W US9507351 W US 9507351W WO 9534320 A3 WO9534320 A3 WO 9534320A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell
inhibits
agent
methods
antibody
Prior art date
Application number
PCT/US1995/007351
Other languages
French (fr)
Other versions
WO1995034320A2 (en
Inventor
Bruce R Blazar
Daniel A Vallera
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Priority to JP8502351A priority Critical patent/JPH10501815A/en
Priority to EP95922279A priority patent/EP0784482A2/en
Priority to AU27018/95A priority patent/AU2701895A/en
Publication of WO1995034320A2 publication Critical patent/WO1995034320A2/en
Publication of WO1995034320A3 publication Critical patent/WO1995034320A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Methods for inhibiting antigen-specific T cell responses by use of an agent which inhibits a costimulatory signal in T cells are disclosed. Preferably, both a first agent which inhibits a costimulatory signal in the T cell (e.g., a CTLA4Ig fusion protein) and a second agent which inhibits another T cell function, such as adhesion of the T cell to a cell presenting antigen to the T cell, are used to inhibit antigen-specific T cell responses. For example, to inhibit adhesion of a T cell to a cell presenting antigen, an anti-LFA-1 antibody can be used in conjunction with a CTLA4Ig fusion protein. Alternatively, another agent which inhibits a costimulatory signal in T cells, such as an anti-B7-1 antibody or an anti-B7-2 antibody can be used with a second agent which inhibits a proliferative signal in the T cell e.g., an anti-IL-2 receptor antibody. The methods of the invention are particularly useful for inhibiting graft versus host disease and for inhibiting rejection of a transplanted tissue or organ.
PCT/US1995/007351 1994-06-07 1995-06-07 Methods for inhibiting antigen specific t cell responses WO1995034320A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP8502351A JPH10501815A (en) 1994-06-07 1995-06-07 Methods for inhibiting antigen-specific T cell responses
EP95922279A EP0784482A2 (en) 1994-06-07 1995-06-07 Methods for inhibiting antigen specific t cell responses
AU27018/95A AU2701895A (en) 1994-06-07 1995-06-07 Methods for inhibiting antigen specific t cell responses

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25526794A 1994-06-07 1994-06-07
US08/255,267 1994-06-07
US47269795A 1995-06-06 1995-06-06
US08/472,697 1995-06-06

Publications (2)

Publication Number Publication Date
WO1995034320A2 WO1995034320A2 (en) 1995-12-21
WO1995034320A3 true WO1995034320A3 (en) 1996-01-18

Family

ID=26944578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/007351 WO1995034320A2 (en) 1994-06-07 1995-06-07 Methods for inhibiting antigen specific t cell responses

Country Status (5)

Country Link
EP (1) EP0784482A2 (en)
JP (1) JPH10501815A (en)
AU (1) AU2701895A (en)
CA (1) CA2191733A1 (en)
WO (1) WO1995034320A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9573999B2 (en) 2005-12-07 2017-02-21 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
US9993550B2 (en) 1999-05-07 2018-06-12 Genentech, Inc. Treatment of pemphigus

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4158396A (en) * 1994-11-10 1996-06-06 Dana-Farber Cancer Institute Methods for inhibiting graft versus host disease in bone marrow transplantation
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP0824594B1 (en) * 1995-05-04 2005-04-06 The United States of America as Representend by The Secretary of the Navy Improved methods for transfecting t cells
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
PT879282E (en) * 1996-01-17 2003-11-28 Imp College Innovations Ltd IMMUNOTHERAPY USING CITOTOXIC T-LYMPHOCYTES (CTL)
IL125928A (en) * 1996-03-20 2002-11-10 Bristol Myers Squibb Co Uses of soluble ligands that interact with gp39, cd40, b7, ctla4 and/or cd28 for preparing pharmaceutical compositions
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
ES2133085B1 (en) * 1996-12-30 2000-04-01 Hospital Universitario Virgen METHOD OF ANALYSIS OF ACUTE REJECTION IN ORTHOTOPIC LIVER TRANSPLANTATION THROUGH THE DETERMINATION OF THE EXPRESSION INTENSITY OF THE CO-STIMULATING MOLECULES (CD28, CTLA-4, CD80 AND CD86) IN THE SURFACE OF LYMPHOCYTES OF PERIPHERAL BLOOD BY FLORA OF PERETHERAL BLOOD.
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO1998056417A1 (en) * 1997-06-11 1998-12-17 The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
WO1999039727A1 (en) * 1998-02-04 1999-08-12 The General Hospital Corporation Costimulatory blockade and mixed chimerism in allotransplantation
US6841347B1 (en) 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
ATE383875T1 (en) 1998-03-17 2008-02-15 Chugai Pharmaceutical Co Ltd PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT CONTAINING ANTAGONISTIC IL-6 RECEPTOR ANTIBODIES
GB9809280D0 (en) 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000014116A1 (en) * 1998-09-04 2000-03-16 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
AU768547B2 (en) * 1999-01-08 2003-12-18 Wisconsin Alumni Research Foundation Methods of prolonging transplant survival using immunotoxins and costimulation blockade of CD154 and CD28
MXPA01008098A (en) 1999-02-12 2002-10-23 Inst Genetics Llc Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith.
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6541608B1 (en) 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
JP2003504005A (en) 1999-02-23 2003-02-04 ベイラー カレッジ オブ メディスィン T cell receptor Vβ-Dβ-Jβ sequence and its detection method
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001068134A2 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies that improve graft survival, using antibodies against a b7 antigen
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1294391B1 (en) * 2000-06-09 2012-08-15 Bristol-Myers Squibb Company Combination of agents for inhibiting transplant rejection
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
WO2002034292A1 (en) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
PT1397153E (en) 2001-05-23 2008-06-12 Bristol Myers Squibb Co Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
KR20050082389A (en) * 2004-02-18 2005-08-23 메덱스젠 주식회사 Pharmaceutical composition for treatment of transplantation rejection comprising concatameric immunoadhesin
ES2385450T3 (en) * 2004-03-22 2012-07-25 Osiris Therapeutics, Inc. Mesenchymal stem cells and their uses
US10508144B2 (en) 2005-12-20 2019-12-17 Bristol-Myers Squibb Company Carbohydrate content of CTLA4 molecules
AR058568A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co METHODS TO PRODUCE A COMPOSITION WITH CTLA4-IG MOLECULES FROM A CROP MEANS
AU2007208504B2 (en) 2006-01-13 2011-04-21 Mesoblast International Sarl Mesenchymal stem cells expressing TNF-alpha receptor
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
AU2019400775A1 (en) * 2018-12-18 2021-07-08 Catapult Therapeutics B.V. The use of anti-CCR7 mAbs for the prevention or treatment of graft-versus-host disease (GvHD)
WO2020172391A1 (en) * 2019-02-22 2020-08-27 The Children's Medical Center Methods and compositions relating to the treatment of gvhd
EP4093508A1 (en) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin antibodies, compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003408A1 (en) * 1993-07-26 1995-02-02 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003408A1 (en) * 1993-07-26 1995-02-02 Dana-Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
B. R. BLAZAR ET AL.: "In vivo infusion of soluble CTLA4-Ig reduces lethal graft-versus-host-disease (GVHD) induced across the major histocompatibility complex (MHC) barrier in mice", BLOOD, vol. 82, no. 10 Suppl. 1, pages 456A *
BRUCE R. BLAZAR ET AL.: "Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host-disease induced by fully major histocompatibility complex-disparate donnor grafts", BLOOD, vol. 85, no. 9, pages 2607 - 2618 *
FRANCES T. HAKIM ET AL.: "Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules", THE JOURNAL OF IMMUNOLOGY, vol. 155, no. 4, pages 1757 - 1766 *
LAURENCE A. TURKA ET AL.: "T-cell activation by CD28 ligand B7 is required for cardiac allograft rejection in vivo", PROC. NATL. ACAD. SCI. USA, vol. 89, pages 11102 - 11105 *
PETER S. LINSLEY ET AL.: "Immunosuppression and the CD28 receptor", PERSPECTIVES IN DRUG AND DISCOVERY DESIGN, vol. 2, no. 1, pages 221 - 231 *
PRABHAKAR BALIGA ET AL.: "CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity", TRANSPLANTATION, vol. 58, no. 10, pages 1082 - 1090 *
STEVEN F. BOLLING ET AL.: "Inhibition of B7-induced CD28 T-cell activation with CTLA4Ig prevents cardiac allograft rejection:evidence for costimulation", SURGICAL FORUM, vol. 43, pages 413 - 415 *
STEVEN F. BOLLING ET AL.: "The effect of combination cyclosporine and CTLA4-Ig therapy on cardiac allograft survival", JOURNAL OF SURGICAL RESEARCH, vol. 57, no. 1, pages 60 - 64 *
THOMAS C. PEARSON ET AL.: "Transplantation tolerance induced by CTLA4-Ig", TRANSPLANTATION, vol. 57, no. 12, pages 1701 - 1706 *
VASSILIKI A. BOUSSIOTIS ET AL.: "B7 but not intercellular adhesion molecule-1 costimulation prevents the induction of human alloantigen-specific tolerance", J. EXP. MED., vol. 178, pages 1753 - 1763 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993550B2 (en) 1999-05-07 2018-06-12 Genentech, Inc. Treatment of pemphigus
US9573999B2 (en) 2005-12-07 2017-02-21 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens

Also Published As

Publication number Publication date
CA2191733A1 (en) 1995-12-21
JPH10501815A (en) 1998-02-17
EP0784482A2 (en) 1997-07-23
WO1995034320A2 (en) 1995-12-21
AU2701895A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
EP1526141A3 (en) MHC complexes and uses thereof
Aragane et al. Involvement of dectin-2 in ultraviolet radiation-induced tolerance
WO1998018826A3 (en) Anti-CCR5 antibodies and methods of use therefor
Dzhambazov et al. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans
EP0757099A3 (en) CTLA4 mutant molecules and uses thereof
AU4485696A (en) Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen
AU3518397A (en) Methods for inducing antigen-specific T cell tolerance
AU1332099A (en) Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
DK0914345T3 (en) Antibodies that bind to monocyte chemoattractant protein-1 receptor (MCP-1 receptor) (CCR2)
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
DK0807178T3 (en) Mycobacterial proteins, microorganisms producing the same and uses of said proteins in vaccines and for the detection of tuberculosis
Henel et al. Uncoupling of T-cell effector functions by inhibitory killer immunoglobulin–like receptors
FI962844A0 (en) T cell antigen receptor V region proteins and methods for their preparation
CA2295604A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
CA2166850A1 (en) Vectors and Use Thereof for Capturing Target Genes
AU3186397A (en) Prion protein binding proteins and uses thereof
DE69840578D1 (en) MANNOSIS RECEPTOR CARRYING CELL LINE AND ANTIGEN COMPOSITION
Haisch et al. A glycoprotein from Schistosoma mansoni eggs binds non‐antigen‐specific immunoglobulin E and releases interleukin‐4 from human basophils
GB9312315D0 (en) Leukocyte adhesion assay
Lanzavecchia Clonal sketches of the immune response.
DK0752102T3 (en) Immunoenzymatic conjugate, method of preparing the conjugate and its use.
Cohen New protein steals the show as' costimulator'of T cells
AR010333A1 (en) AN OB MUTEIN, A DNA SEQUENCE, A VECTOR OF EXPRESSION A PROCARIOT OR MAMMAL HOSPITAL CELL, A RECOMBINANT BACULOVIRUS, A CELL PHONE, A METHOD FOR THE PRODUCTION OF AN OB MUTEIN, A PHARMACEUTICAL COMPOSITION, THE USE PREPARATION OF A COMPOSI

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2191733

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995922279

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995922279

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995922279

Country of ref document: EP